Under this new order, the US Centers for Disease Control and Prevention (CDC) has agreed to procure10 million doses in addition to the 182.5 million doses of ACAM2000 Acambis has already delivered.
The UK-based company added that advanced negotiations are continuing to finalize the long-term warm-base manufacturing contract, which is expected to be awarded following licensure of ACAM2000, currently undergoing review from the FDA.
Gordon Cameron, CEO of Acambis, said: “This agreement from the CDC clearly demonstrates the US government’s commitment to ACAM2000 warm-base manufacturing for the long term. We look forward to securing a long-term warm-base manufacturing contract shortly after the expected licensure of ACAM2000 in early 2007.”
Meanwhile, Acambis unveiled a second quarter loss before tax of GBP11.5 million compared to a loss of GBP7 million in the same period last year. Revenues fell to GBP4.6 million from GBP6.4 million.